Ziv-Aflibercept Use in Metastatic Colorectal Cancer
Mabel Rodriguez, PharmD
From Memorial Sloan-Kettering Cancer Center, New York, New York
The author has no conflicts of interest to disclose.
Correspondence to: Mabel Rodriguez, PharmD, Memorial Sloan-Kettering Clinical Pharmacy Department, 1265 York Avenue S-710, New York, NY 10065. E-mail: email@example.com
J Adv Pract Oncol 2013;4:348–352 |
DOI: 10.6004/jadpro.2013.4.5.6 |
© 2013 Harborside Press®
In August 2012, ziv-aflibercept (Zaltrap) was approved by the FDA for use in combination with FOLFIRI in certain oxaliplatin-refractory patients with mCRC. Read about the mechanism of action, key trials, and management strategies associated with this VEGF pathway targeted agent.
For access to the full length article, please sign in